Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer
FDA granted accelerated approval to Mirati’s KRAS drug adagrasib, which will be marketed as Krazati. The green light comes two days ahead of the expected decision and cements the biotech as the second in the KRAS field behind leader Amgen, maker of the May 2021-approved Lumakras.
The nod is for second-line treatment for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.